A designer drug against influenza: The NA inhibitor oseltamivir (Tamiflu®)

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 337-341

  Oxford, J S ^a   Mann, A ^a   Lambkin, R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Clinical trial; Epidemic; Influenza; M2 blockers; Neuraminidase inhibators; NICE; Pandemic; SARS

Indexed keywords

DESIGNER DRUG; INFLUENZA VACCINE; OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG USE; EMERGENCY HEALTH SERVICE; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHIBITION KINETICS; MASS MEDIUM; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; PANIC; PRESCRIPTION; PUBLIC HEALTH; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TELEPHONE; UNITED KINGDOM; VIRUS REPLICATION; VIRUS STRAIN;

ACETAMIDES; ANIMALS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR;

EID: 3042699643     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 118-123 (1993).
2. Kim CU, Lew W, Williams MA et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41, 2451-2460 (1998).
3. Gottschalk A. The specific enzyme of influenza virus and vibrio cholerae. Biochemica et Biophysica Acta 23, 645 (1957).
4. Stuart-Harris CH, Schild GC, Oxford JS. In: Influenza, the Viruses and the Disease. E Arnold, London, UK, 2264 (1984).
5. Wilson IA, Skehel JJ, Wiley DC. Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3A resolution. Nature 289, 366 (1981).
6. Wrigley NG, Skehel JJ, Charlwood PA, Brand CM. The size and shape of influenza virus neuraminidase. Virology 51, 525 (1973).
7. Laver WG. Structural studies on the protein subunits from three strains of influenza virus. Mol. Biol. 9, 109 (1964).
8. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303, 41 (1983).
9. Catchpole AP, Mingay LJ, Fodor E, Brownlea GG. Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene. J. General Virol. 84, 507-515 (2003).
10. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt KI, Wane M. Influenza vaccination and reduction in hospitalisation for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348, 1322-1332 (2003).
11. Oxford, JS, Novelli P, Sefton A, Lambkin R. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antiviral Chem. Chemother. 13, 205-217 (2002).
12. Peiris (2003).
13. Oxford JS, Bossuyt S, Lambkin R. A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus. Immunology 109, 1-3 (2003).
14. Galbraith AW, Oxford JS Schild GC, Watson GL. Protective effect of L-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 2, 1026-1028 (1969).
15. Welliver R, Monto AS, Carewitc O et al. Effectiveness of oseltamivir in preventing influenza in household contacts. J. Am. Med. Ass. 285, 748-754 (2001).
16. Hayden FG, Atmar RL Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 341, 1336-1343 (1999).
17. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomised controlled trial. US Oral Neuraminidase Study Group. J. Am. Med. Assoc. 283, 1016-1024 (2000).
18. Nicholson KG, Aoki FY, Osterhaus ADME et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355, 1845-1850 (2000).
19. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediat. Infect. Dis. J. 20, 127-133 (2001).
20. Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltaminir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51, 123-129 (2003).
21. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuramanidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55, 307-317 (2002).
22. Meindl P, Tuppy H. Desoxy-2,3-dehydrosialinsauren, II, competitive hemmung der vibrio-cholerae-neuraminidase durch 2-desoxy-2,3-dehdro-N-neuramin-sauren. [2-deosy-2,3-dehytrosialic acids II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2, 3-dehydro-N-Acylneuramimic acids]. Hoppe Seyler's Z fur Physiol Chemie 350, 1088-1092 (1969).
23. Oxford JS. A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev. Med. Virol. 10, 119-133 (2000).
24. Oxford JS, Novelli P, Sefton A, Lambkin R. New millennium antivirals against pandemics and epidemic influenza: the neuraminidase inhibitors. Antiviral Chem. Chemother. 13, 205-217 (2002).
25. Yuen KY, Chan PK, Peiris M et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351, 467-471 (1998).